ALK5 inhibition in renal disease.

Laping, Nicholas J

Laping, Nicholas J.

Affiliation

Laping NJ; GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, PO 1539 King of Prussia, PA 19406, USA. nicholas_j_laping@gsk.com

Curr Opin Pharmacol ; 3(2): 204-8, 2003 Apr.

Article in En | MEDLINE | ID: mdl-12681245

Subject(s)

Activin Receptors, Type I/antagonists & inhibitors; Activin Receptors, Type I/physiology; Kidney Diseases/metabolism; Receptors, Transforming Growth Factor beta/antagonists & inhibitors; Receptors, Transforming Growth Factor beta/physiology; Animals; Humans; Kidney Diseases/drug therapy; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Signal Transduction/drug effects; Signal Transduction/physiology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Transforming Growth Factor beta / Activin Receptors, Type I / Kidney Diseases Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Curr Opin Pharmacol Journal subject: FARMACOLOGIA Year: 2003 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links